Should I Buy AEON? AEON 2026 Analysis

Should You Buy Aeon Biopharma Inc (AEON) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.100

1 Day change

2.80%

52 Week Range

10.010

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: no Intellectia buy signals, weakening momentum (MACD), and the nearest pattern-based projection points to further downside over the next month.
With no recent news catalysts and continued losses/no revenue, the risk-reward is unfavorable for an impatient buyer seeking an immediate entry.
Best call here is to avoid/new-buy (and trim/sell if you’re already positioned) until price reclaims key levels (pivot ~1.228+) with improving momentum.

Technical Analysis

Trend/structure: Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader structure has improved, but it’s not being confirmed by momentum.
Momentum: MACD histogram is negative (-0.0105) and negatively expanding → bearish momentum building despite the MA stack.
RSI(6): ~50.1 (neutral) → no oversold bounce signal and no strong bullish thrust.
Key levels: Price 1.17 is below pivot 1.228 (bearish positioning). Support S1 ~1.111 (break risks push toward S2 ~1.04). Resistance R1 ~1.345.
Pattern-based outlook: Similar-pattern stats imply ~-7.26% over the next month (near-term expected edge is not favorable).

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

- NULL identified in the last week (no recent news provided).
- Short-term pre-market/regular market uptick is marginally positive, but not supported by momentum signals.

Neutral/Negative Catalysts

- No news/catalysts to drive a breakout, leaving the stock to trade mostly on technicals and risk appetite.
- Momentum deterioration (MACD worsening) while price sits below pivot resistance.
- Pattern-based forward bias indicates elevated probability of drawdown over the next month.
- Trading trends: hedge funds neutral; insiders neutral (no supportive accumulation signals).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 0 (no operating revenue; no YoY growth contribution).
Net income: -4.538M (loss widened ~26.46% YoY) → worsening profitability.
EPS: -0.39 (down ~96.53% YoY) → materially weaker per-share results.
Overall: financial trajectory is not improving in a way that typically supports durable upside without a clear external catalyst.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target changes were provided in the data, so there’s no observable recent Wall Street trend to lean on.
Practical pro view (inferred from available data): limited—lack of visible institutional/insider accumulation signals and no near-term catalysts.
Practical con view: ongoing losses with no revenue, making sentiment highly dependent on speculative catalysts that are not currently present.

Analyst Rating

Wall Street analysts forecast AEON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AEON is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold